Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Takara Bio Announces Launch of Human iPSC-derived Intestinal Epithelial Cells for Drug Discovery Research

November 12, 2019 GMT

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Nov 12, 2019--

Takara Bio USA, Inc. (TBUSA) announced that its parent company, Takara Bio Inc., has launched the world’s first commercially available small intestinal epithelial cells derived from human induced pluripotent stem cells. The new Cellartis® Intestinal Epithelial Cells (from ChiPSC18) Kit was jointly developed when Takara Bio received a technology transfer from a differentiation induction method to derive these cells from hiPSCs. This method was studied and developed by Dr. Hiroyuki Mizuguchi (Professor of Graduate school of Pharmaceutical Sciences, Osaka University, Project Leader of the National Institutes of Biomedical Innovation, Health and Nutrition) and Dr. Kazuo Takayama (Assistant Professor, Osaka University).

These hiPSC-derived cells express intestinal markers at levels comparable to that of adult small intestinal tissue. They also express drug metabolizing enzyme CYP3A4 and drug transporter PEPT1 at more physiologically relevant levels compared with Caco-2, the current gold standard of intestinal models. Additionally, the monolayer of intestinal epithelial cells forms a functional barrier that can be used for predicting intestinal permeability. Altogether, these cells provide an improved model for the study of absorption and metabolism of orally administered drugs.

Previously made available in Japan, TBUSA has now decided to bring the cells to the US. “Takara Bio is pleased to expand our portfolio of products and services that support disease modeling and drug discovery,” said Carol Lou, President of TBUSA. “The Cellartis Intestinal Epithelial Cells (from ChiPSC18) Kit complements our Cellartis Power Primary HEP Medium to enable more comprehensive and accurate drug metabolism studies that will accelerate the drug discovery process.”

About Takara Bio

Takara Bio USA, Inc. (TBUSA) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for life sciences research applications, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191112005064/en/

CONTACT: Lorna Neilson, PhD

VP, Corporate Development





SOURCE: Takara Bio USA, Inc.

Copyright Business Wire 2019.

PUB: 11/12/2019 09:00 AM/DISC: 11/12/2019 09:01 AM